What are the causes and incidence of right heart failure?
The causes of right heart failure (RHF) are diverse and include acute myocardial infarction (MI), post-surgery or heart transplant, and left ventricular assist device (LVAD) implantation, and pulmonary embolism.
|Cause of RHF||Incidence of RHF|
|After heart transplant||2-3%3|
|Acute myocardial infarction||about 50%4|
How is right heart failure diagnosed?
Given that right ventricular failure (RVF) is a hemodynamic problem, assessment of hemodynamic parameters including central venous pressure (CVP), cardiac output or index, using the pulmonary artery (PA) catheter in combination with cardiac echocardiography represents the gold standard for evaluation of RV function. Kapur et al. suggest the following hemodynamic variables to assess RV function and the cut-off values depending on the etiology of RVF.6
Table 1. Hemodynamic Formulas to Assess Right Ventricular Function
|Hemodynamic Formulas to Assess RV Function|
|Cardiac filling pressures||RAP/PCWP||>0.63 (RVF after LVAD)13|
>0.86 (RVF in acute MI)30
|PA pulsatility index|
|(PASP-PADP)/RAP||<1.85 (RVF after LVAD)31|
<1.0 (RVF in acute MI)32
|Pulmonary vascular resistance||mPAP-PCWP/CO||>3.6 (RVF after LVAD)15|
|Diastolic pulmonary gradient||PADP-PCWP||Undetermined33,34|
|RV stroke work||(mPAP-RAP)x|
|<15 (RVF after LVAD)15|
<10 (RVF after acute MI)35
|RV stroke work index||(mPAP-RAP)/SV index||<0.3-0.6 (RVF after LVAD)13,31|
|PA compliance||SV/(PASP-PADP)||<2.5 (RVF in chronic heart failure)|
Three-dimensional echocardiography represents an accurate method to assess RV size, contractility and ejection fraction.1 The American Society of Echocardiography (ASE) suggests quantitative assessment of RV function by at least one of the following parameters:1,7
- Tricuspid annular plane systolic excursion (TAPSE, normal reference limit ≥ 18 mm)
- RV fractional area change (RVFAC, normal value > 35%)
- RV tissue Doppler S velocity (normal value > 10 cm/s) of the tricuspid annulus.
Which Impella device is FDA-approved for right heart failure?
The Impella RP is the only device designated by the FDA as a safe and effective therapy for right heart failure. The Impella RP received FDA pre-market approval (PMA) for use in acute heart failure on September 20, 2017 (P170011).8
The Impella RP is a 22 Fr 3-D catheter-based micro-axial pump approved by the U.S Food and Drug Administration (FDA) for use in acute RHF for up to 14 days.9 The catheter pump is advanced antegrade under fluoroscopic guidance over a 0.027-inch platinum super-stiff wire and positioned across the tricuspid and pulmonary valves through a 23 Fr peel-away sheath inserted in the femoral vein. The pump inflow is positioned in the inferior vena cava (IVC) and the outflow in the pulmonary artery (PA); thus, the pump aspirates blood from the IVC and expels it into the PA at a rate of up to 4 L/min, thereby directly bypassing the RV.
What clinical evidence was used for FDA approval of Impella RP for acute right heart failure?
Impella RP is the most studied right-sided device and the only percutaneous technology with FDA approval designating it as safe and effective for right heart support. Its exclusive FDA approval is a result of five years of research that included:10
- RECOVER RIGHT, an FDA-approved, prospective, multicenter, single-arm study, which commenced after the company received FDA investigational device exemption (IDE) approval in November 2012 and concluded in 2014.
- HDE approval study, which was completed in January 2015
- A Continuous Access Protocol (CAP)
|Data Source||30-day Survival Rate|
|PMA control group data (non-Impella surgical device) (n=24)||43% (10/24)|
|RECOVER RIGHT (RR, Impella RP) (n=30)||73.3% (22/30)|
|Premarket clinical studies (RR + CAP + HDE PAS) (n=60)||73% (44/60)|
What are the results of the post-approval study of Impella RP?
|Post-Approval Study (PAS) — (N=42)||30-day Survival|
|Recover Right Protocol Population (N=14)||64% (9/14)|
|Salvage Patient Population (N=28)||11% (3/28)|
The 18-month post-approval study (PAS) submitted to the FDA for Impella RP included 42 patients.11 Of the 42 patients, the FDA determined that only 14 patients met the inclusion criteria for the Recover Right pre-market trial and 28 patients received Impella RP as a salvage therapy. Salvage patients were those who received Impella RP > 48 hours after cardiogenic shock and those who sustained out-of-hospital cardiac arrest.
Based on the survival rate of 64% in non-salvage patients, the FDA validated that the post-approval study demonstrates Impella RP is safe and effective for treatment of right heart failure.10
What are the best practices for use of Impella RP for right-sided support?
Abiomed encourages clinicians to select patients and time Impella RP implantation appropriately. Clinicians should review the inclusion and exclusion criteria for Impella RP and follow guidelines, which recommend implantation of Impella RP within 48 hours of cardiogenic shock onset caused by right side failure.
On the basis of best practices identified in multiple clinical studies and in accordance with the inclusion and exclusion criteria of RECOVER RIGHT, healthcare providers are encouraged to use the Impella RP checklist, on which the FDA and Abiomed collaborated to develop, to assist with proper patient selection to optimize outcomes. This checklist helps determine if Impella RP is an appropriate treatment option for the patient.
- Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2018;137:e578—e622.
- Lampert BC and Teuteberg JJ. Right ventricular failure after left ventricular assist devices J Heart Lung Transplant 2015;34:1123—1130.
- Grignola JC, Domingo. Acute Right Ventricular Dysfunction in Intensive Care Unit. Biomed Res Int. 2017; 2017: 8217105.
- Goldstein JA, Kern MJ. Percutaneous mechanical support for the failing right heart. Cardiol Clin 2012;30:303-10.
- Estrada VHN, Franco DLM, et al. Postoperative Right Ventricular Failure in Cardiac Surgery. Cardiol Res. 2016;7(6):185-195.
- Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, Burkhoff D. Mechanical circulatory support devices for acute right ventricular failure. Circulation. 2017; 136:314—326.
- Harjola VP, Mebazaa A, Čelutkienė J, al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226-41.
- FDA-P170011B. Impella Ventricular Support Systems - P170011B. 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170011B.pdf. Accessed 19 June 2019.
- Pieri M, Pappalardo F. Impella RP in the Treatment of Right Ventricular Failure: What We Know and Where We Go. J Cardiothorac Vasc Anesth. 2018;32(5):2339-2343.
- Abiomed Press Releases. FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval. http://investors.abiomed.com/news-releases/news-release-details/fda-confirms-impella-rp-safe-and-effective-only-right-sided. Accessed June 19, 2019.
- Abiomed Press Releases. Impella RP Post-Approval Study Data Presented at ACC 2019. http://investors.abiomed.com/news-releases/news-release-details/impella-rp-post-approval-study-data-presented-acc-2019. Accessed June 19, 2019.